Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2002799 | 0.79 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2HPGDHSD17B10KMT2A | |
| SCHEMBL29139348 | 0.77 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2HPGDHSD17B10KMT2A | |
| SCHEMBL29112231 | 0.77 | HDAC1 (0.33) | KMT2AMEN1PKMLMNA | |
| SCHEMBL23235917 | 0.73 | LMNA (0.39) | ALDH1A1SMN1; SMN2HPGDHSD17B10KMT2A | |
| SCHEMBL616909 | 0.73 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2HPGDHSD17B10KMT2A | |
| SCHEMBL179878 | 0.72 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2HPGDHSD17B10KMT2A | |
| Succinimide SCHEMBL25387343 | 0.71 | SMN1; SMN2 (0.46) | ALDH1A1SMN1; SMN2HPGDHSD17B10KMT2A | |
| SCHEMBL21768397 | 0.70 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2HPGDHSD17B10KMT2A | |
| SCHEMBL1578256 | 0.69 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2HPGDHSD17B10KMT2A | |
| SCHEMBL23235912 | 0.69 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2HPGDHSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2019 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3404043-B1 | ANTI-CDH3 ANTIBODY HAVING HIGH INTERNALIZATION CAPACITY | PERSEUS PROTEOMICS INC (JP) | 2022-10-26 | — | — | EP | claimed |
| US-20220257789-A1 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | EXELIXIS, INC. | 2022-08-18 | — | — | US | claimed |
| EP-3994150-A1 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | Iconic Therapeutics, Inc. (US) | 2022-05-11 | — | — | EP | claimed |
| WO-2021003399-A1 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | ICONIC THERAPEUTICS, INC. (US) | 2021-01-07 | — | — | WO | claimed |
| EP-3708586-A1 | ANTI-CDH3 ANTIBODY HAVING HIGH INTERNALIZATION CAPACITY | Perseus Proteomics Inc. (JP) | 2020-09-16 | — | — | EP | claimed |
| US-20200155701-A1 | HERCEPTIN® ADJUVANT THERAPY | GENENTECH, INC. (US) | 2020-05-21 | — | — | US | claimed |
| US-20200048362-A1 | METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES | IMMUNOGEN INC (US) | 2020-02-13 | — | — | US | claimed |
| EP-3126383-B1 | MODIFIED J-CHAIN | IGM BIOSCIENCES AS (DK) | 2018-12-19 | — | — | EP | claimed |
| EP-3404043-A1 | ANTI-CDH3 ANTIBODY HAVING HIGH INTERNALIZATION CAPACITY | Perseus Proteomics Inc. (JP) | 2018-11-21 | — | — | EP | claimed |
| US-20180236093-A1 | HERCEPTIN® ADJUVANT THERAPY | GENENTECH INC (US) | 2018-08-23 | — | — | US | claimed |
| WO-2009140242-A1 | ANALYSIS OF ANTIBODY DRUG CONJUGATES BY BEAD-BASED AFFINITY CAPTURE AND MASS SPECTROMETRY | GENENTECH, INC. (US) | 2009-11-19 | — | — | WO | claimed |
| US-20090286258-A1 | ANALYSIS OF ANTIBODY DRUG CONJUGATES BY BEAD-BASED AFFINITY CAPTURE AND MASS SPECTROMETRY | GENENTECH, INC. | 2009-11-19 | — | — | US | claimed |
| US-20080226659-A1 | Cancer treatment | IMMUNOGEN, INC. | 2008-09-18 | — | — | US | claimed |
| EP-1740954-A1 | MASS SPECTROMETRY OF ANTIBODY CONJUGATES | Kadkhodayan, Miryam (US) | 2007-01-10 | — | — | EP | claimed |
| US-7097840-B2 | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates | GENENTECH, INC. (US) | 2006-08-29 | — | — | US | claimed |
| WO-2005101017-A1 | MASS SPECTROMETRY OF ANTIBODY CONJUGATES | GENENTECH, INC. (US) | 2005-10-27 | — | — | WO | claimed |
| JP-2003503365-A | — | — | 2003-01-28 | — | — | JP | claimed |
| EP-1191944-A2 | METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES | Genentech, Inc. (US) | 2002-04-03 | — | — | EP | claimed |
| US-20020001587-A1 | Tyrosine kinases; cell differentiation; epidermal growth factor receptor; antitumor agents | IMMUNOGEN, INC. | 2002-01-03 | — | — | US | claimed |
| WO-2001000244-A2 | METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES | GENENTECH, INC. (US) | 2001-01-04 | — | — | WO | claimed |